Despite a great deal of original research into Australian snakes and their complex venoms, there is still confusion about the correct first-aid and hospital management of the bitten patient. This review illustrates the difficulties in diagnosis and treatment and presents a well tried protocol for the successful management of snake bite.
Finally, it has become most important medico-Iegally to have a well-understood cohesive policy on the management of snake bite accepted throughout the hospital. This has been highlighted by two recent coroners' investigations.
Australian Snakes and Venoms:
A great deal of information is available regarding the type of venomous snakes and the action of their toxins , Cogger 1975 , Garnett 1972 , Sutherland 1974 , Sutherland, Coulter and Harris 1978 . Australian snakes possess some of the most complex and potent polypeptide venoms in the world, and a recent discovery, the "small-scaled" or "fierce" snake of Central Australia has a particularly potent venom .
The effects of Australian snake venoms may be summarized as follows:-(a) Multiple Neurotoxins: These are believed to act peripherally at both the pre-synaptic and post-synaptic areas of the neuro muscular junction (NMJ) . (b) Potent Myotoxins: Skeletal muscle seems to be particularly affected, with the pre-synaptic neurotoxin being especially myolytic. ( c) Anticoagulants: These are usually very weak, but commonly include in vitro coagulation abnormalities.
(d) H aemolysins:
Whilst the latter two are less common clinically, quite an amount of information is available on the mechanisms of action of venom on the coagulation cascade and the haemolytic effects (Denson, Borrett and Biggs 1971) .
Last year over 200 patients in Australia required antivenene, and it is estimated that there were 10 to 15 deaths as a result of snake bite or its treatment. However, there are probably many more unsuspected or poorly documented bites, and probably a number of unrecorded deaths because of absent history or sub-optimal treatment (Sutherland 197 8a Two recent fatalities involving children have illustrated the fact that snake bite must be included in the differential diagnosis when any adult or child presents with a combination of the following:-(a) Nausea and vomiting; (b) symptoms and signs of recent muscle weakness of unknown origin, such as diplopia, ptosis and ventilatory inadequacy; (c) conscious state impairment.
Venom detection is possible, using a radioimmunoassay technique (Sutherland and Coulter 1977) , and the assay can be performed as an emergency procedure. The presence of myoglobinuria has recently been recognized as an important early feature of systemic envenomation, and is easily detected (Sutherland 1978a) . A sharp rise in serum creatine kinase (CK) levels is another common feature of systemic envenomation, and is also easily detected (Gaynor 1977) .
Distribution of Common Venomous Australian Snakes:
(a) VICTORIA -Brown and Tiger. (b ) TASMANIA -Tiger and Copperhead. (c) REMAINDER Predominantly Brown and Death Adder.
In addition, the Taipan is found in northern coastal areas, and a recent discovery has been the "small-scaled" or "fierce" snake, found in large areas of Central Australia , Sutherland 1978a ). Fortunately, Polyvalent or Taipan antivenene is effective in neutralizing the venom of this highly dangerous snake. ~
Because one type of snake tends to look very like another, it is best to plan treatment on the basis of the type of venomous snake likely to be found in the area. Routine identification can only be made by an expert able to pick out the fine distinguishing features of a particular species.
Causes of Death:
1. Ventilatory failure: This is by far the most common cause of death.
Incorrect use of Antivenene:
(a) Incorrect antivenene will have no clinical effect. Cb) Correct antivenene, given too slowly may fail to fully neutralize circulating venom. This problem may occur in children because of more rapid venom movement, and may also occur in multiple bites because of the larger depot of venom.
(c) A naphylactic reactions to antivenene:
Antivenene is prepared by cquine inoculation so the potential for anaphylactic response is quite high. About 33% of patients given antivenene will suffer some reaction, but less than 1 % will experience a major sensitivity reaction (Sutherland 1979 (b) ).
Coagulation disturbances:
These are commonly noted, especially prolongation of kaolin activated partial thromboplastin time (PTTK). Mortality from clinical haemorrhage is most uncommon, but a death from sub-arachnoid haemorrhage has recently occurred in Queensland (Sutherland 1979 (c) ).
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First Aid:
Until recently the accepted view was that an arterial tourniquet should be used. However, recent experimental work has shown that central venom movement occurs mainly via lymphatic pathways, and to a lesser degree by venous return. Therefore, the current recommendations for first aid are: (Sutherland et al. 1979 ).
(a) Apply a very firm local dressing over the bitten area, and as much of the limb as possible, and (b) Immobilize the affected limb. This course of action is designed to prevent venom movement from the bitten area. There is absolutely no indication for incision or excision of the bitten area, nor is there any indication for the use of either an arterial or a venous tourniquent (Sutherland 1979a ).
On Admission:
Immobilization should be maintained and local pressure dressing should be removed. However, if signs of systemic envenomation occur rapidly, this "pressure dressing" should be reapplied fully whilst antivenene is administered and circulating venom neutralized. This technique may be of great assistance in regulating release of venom during organization of definitive treatment. (Sutherland 1978a) . (b) Rapid rise in CK levels is another reliable early diagnostic sign. (c) Coagulation disturbances are common, especially those involving the intrinsic pathway. Partial thromboplastin time (PTTK) is commonly prolonged, but haematological advice may be required to assess the relevance of the coagulopathy in the overall clinical setting. Notwithstanding, PTTK should be repeated hourly during the initial period of observation (Sutherland 1978b) .
In summary, detection of any or all of the following signs of systemic envenomation represent an absolute indication for the use of antivenene.
( Before antivenene infusion is commenced, a small sample (approx. 2 ml) of serum and urine should be collected and frozen for possible later venom identification (Sutherland and Coulter 1977) .
Supportive Care:
On admission to the intensive care area, an intravenous drip is inserted and blood taken for full blood examination, urea and electrolytes, clotting studies (PTTK) and creatine kinase levels. Vrine should be collected, by catheter if necessary, and examined for presence of myoglobin. These investigations may need to be repeated regularly, especiaIIy if the use of antivenene is indicated.
Assisted ventilation may be required, so facilities for intubation and artificial ventilation should be immediately available. If antivenene is to be used, equipment and drugs to treat anaphylaxis should also be immediately at hand.
Technique of Antivenene Administration:
1. Dose of Antivenene to be used: It should be noted that this protocol applies to the situation where the snake has not been positively identified. 
Important Features of Antivenene Use:
(a) The same dose of antivenene should be used in a child as in an adult. One dose of antivenene is designed to negate the effects of an average bite, and so subsequent doses may be necessary where mUltiple bites have occurred, or where re-envenomation has occurred. (b) Antivenene must be given intravenously to have any worthwhile effect. (c) Patients must be closely observed after antivenene administration. Thirty per cent (30%) of patients will require a second dose of antivenene because of persisting clinical or laboratory abnormalities (Sutherland 1979c 
